653 related articles for article (PubMed ID: 17134822)
1. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
5. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.
Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP
Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590
[TBL] [Abstract][Full Text] [Related]
6. RING1 interacts with multiple Polycomb-group proteins and displays tumorigenic activity.
Satijn DP; Otte AP
Mol Cell Biol; 1999 Jan; 19(1):57-68. PubMed ID: 9858531
[TBL] [Abstract][Full Text] [Related]
7. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
[TBL] [Abstract][Full Text] [Related]
8. A panel of monoclonal antibodies against human polycomb group proteins.
Hamer KM; Sewalt RG; den Blaauwen JL; Hendrix T; Satijn DP; Otte AP
Hybrid Hybridomics; 2002 Aug; 21(4):245-52. PubMed ID: 12193277
[TBL] [Abstract][Full Text] [Related]
9. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
10. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene.
Raaphorst FM; Meijer CJ; Fieret E; Blokzijl T; Mommers E; Buerger H; Packeisen J; Sewalt RA; Otte AP; van Diest PJ
Neoplasia; 2003; 5(6):481-8. PubMed ID: 14965441
[TBL] [Abstract][Full Text] [Related]
12. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
[TBL] [Abstract][Full Text] [Related]
13. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.
Sánchez-Beato M; Sánchez E; González-Carreró J; Morente M; Díez A; Sánchez-Verde L; Martín MC; Cigudosa JC; Vidal M; Piris MA
Mod Pathol; 2006 May; 19(5):684-94. PubMed ID: 16528373
[TBL] [Abstract][Full Text] [Related]
14. Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes.
Sewalt RG; van der Vlag J; Gunster MJ; Hamer KM; den Blaauwen JL; Satijn DP; Hendrix T; van Driel R; Otte AP
Mol Cell Biol; 1998 Jun; 18(6):3586-95. PubMed ID: 9584199
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
17. Expression parameters of the polycomb group proteins BMI1, SUZ12, RING1 and CBX7 in urothelial carcinoma of the bladder and their prognostic relevance.
Hinz S; Kempkensteffen C; Christoph F; Krause H; Schrader M; Schostak M; Miller K; Weikert S
Tumour Biol; 2008; 29(5):323-9. PubMed ID: 18984978
[TBL] [Abstract][Full Text] [Related]
18. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis.
Breuer RH; Snijders PJ; Smit EF; Sutedja TG; Sewalt RG; Otte AP; van Kemenade FJ; Postmus PE; Meijer CJ; Raaphorst FM
Neoplasia; 2004; 6(6):736-43. PubMed ID: 15720799
[TBL] [Abstract][Full Text] [Related]
20. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
